French recall of Abbott AxSYM and IMx lots:
This article was originally published in Clinica
Executive Summary
Abbott Diagnostics has recalled certain lots of its AxSYM and IMx in vitro diagnostic products on the French market. The recall, says the French healthcare products safety agency, AFSSAPS, affects lots 89273M300 and 89470M200 of its AxSYM (reference number 3C79-20) and lots 75782M200 and 75998M200 of its IMx (reference number 2200-20). These products are involved in the dosification of vitamin B12 in serum and plasma.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.